FDA approves AstraZeneca's Imfinzi combination for high-risk bladder cancer

The U.S. Food and Drug Administration approved AstraZeneca's (NYSE:AZN) blockbusting immunotherapy Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, marking a major regulatory expansion for the company’s oncology franchise into earlier-stage disease.

The clearance provides a new treatment paradigm for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).

The decision addresses a critical bottleneck in urological oncology, representing the first new therapeutic regimen approved in more than three decades for this specific patient population.

NMIBC is a localized, early form of cancer that hasn't yet grown into the main muscle wall of the bladder, but high-risk variants frequently recur or progress, historically forcing patients into repetitive surgeries or total bladder removal.

The standard of care for the estimated 31,000 Americans treated for high-risk NMIBC annually has long been limited to surgical tumor resection followed by standard BCG instillations directly into the bladder.

Despite this curative-intent approach, up to 80% of high-risk patients experience a return of their disease within five years.

AstraZeneca's newly approved combination effectively shifts the treatment standard by overlaying a systemic checkpoint inhibitor onto local immunotherapy.

The FDA decision is anchored by data from the pivotal POTOMAC Phase III clinical trial, which originally debuted at the European Society for Medical Oncology Congress 2025 and was published in The Lancet.

Results from the trial demonstrated that adding one year of Imfinzi treatment to traditional BCG induction and maintenance reduced the relative risk of high-risk disease recurrence, progression, or death by 32% compared to utilizing BCG alone.

The clinical benefit was supported by a disease-free survival hazard ratio of 0.68.

Long-term follow-up data validated the durability of the regimen.

Over a median tracking period of more than five years (60.7 months), the Imfinzi-led combination delivered an early and sustained survival benefit, diverging favorably from the control group within the first four months of starting therapy.

The exact median disease-free survival has not yet been reached for either arm of the trial, indicating extended remission periods across the patient cohort.

The addition of the checkpoint inhibitor did not introduce unexpected toxicities or compromise primary patient care.

The safety and tolerability profile of the dual regimen proved fully consistent with the established profiles of the individual drugs, yielding no new safety signals over the five-year observation window.

Furthermore, the protocol did not hinder patients' capacity to complete their baseline BCG induction and maintenance cycles, nor did it cause any meaningful deterioration in patient-reported quality-of-life metrics.